Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does LINAGLIPTIN Cause Disturbance in attention? 350 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 350 reports of Disturbance in attention have been filed in association with LINAGLIPTIN (Linagliptin and metformin hydrochloride). This represents 4.5% of all adverse event reports for LINAGLIPTIN.

350
Reports of Disturbance in attention with LINAGLIPTIN
4.5%
of all LINAGLIPTIN reports
0
Deaths
98
Hospitalizations

How Dangerous Is Disturbance in attention From LINAGLIPTIN?

Of the 350 reports, 98 (28.0%) required hospitalization, and 98 (28.0%) were considered life-threatening.

Is Disturbance in attention Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for LINAGLIPTIN. However, 350 reports have been filed with the FAERS database.

What Other Side Effects Does LINAGLIPTIN Cause?

Blood glucose increased (804) Dyspnoea (571) Dizziness (529) Pruritus (527) Nausea (525) Diarrhoea (509) Vomiting (465) Fatigue (464) Malaise (457) Arthralgia (446)

What Other Drugs Cause Disturbance in attention?

LEVOTHYROXINE (1,718) METHYLPHENIDATE (1,414) AMPHETAMINE ASPARTATE\AMPHETAMINE\DEXTROAMPHETAMINE SACCHARATE\DEXTROAMPHETAMINE (1,321) DULOXETINE (986) PREGABALIN (950) LISDEXAMFETAMINE DIMESYLATE (911) OXYCODONE (829) QUETIAPINE (747) ACETAMINOPHEN\HYDROCODONE (746) ACETAMINOPHEN\OXYCODONE (734)

Which LINAGLIPTIN Alternatives Have Lower Disturbance in attention Risk?

LINAGLIPTIN vs LINAGLIPTIN\METFORMIN LINAGLIPTIN vs LINCOMYCIN LINAGLIPTIN vs LINEZOLID LINAGLIPTIN vs LINZESS LINAGLIPTIN vs LIORESAL

Related Pages

LINAGLIPTIN Full Profile All Disturbance in attention Reports All Drugs Causing Disturbance in attention LINAGLIPTIN Demographics